Exhibit 10-12
THE SYMBOL '***' IS USED THROUGHOUT THIS EXHIBIT TO INDICATE THAT A PORTION OF THE EXHIBIT HAS BEEN OMITTED AS CONFIDENTIAL
United States Public Health Service
Amendment L-103-96/1
This first Amendment ("Amendment") to the License Agreement L-103-96/0 entered into on November 19, 1997 (the "Original Agreement") by the Public Health Service (hereinafter "PHS") through the Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland, 20852-3804 and Angiotech Pharmaceuticals, Inc. (hereinafter "Licensee"), a Canadian corporation having its principal office at 6660 N.W. Marine Drive, Vancouver, B.C. CANADA, V6T 1 Z4, is effective as of the last signature date below.
WHEREAS,
A.
TheOriginal Agreementby and betweenPHSandLicensee grantsLicensee, among other things, an exclusive license under theLicensed Patent Rights in theLicensed Territory to make and have made, to use and have used, to sell and have sold, to offer to sell, and to importLicensed Productsin the LicensedFields ofUse and to practice and have practiced anyLicensed Processes in theLicensed Fields of Use.
B.
As Licenseemade payments in lieu of an earned royalty to enter into a License Agreement with NeoRx Corporation ("NeoRx"), pursuant to which NeoRx granted Licensee an exclusive license to certain technology, patents and other intellectual property rights covering the manufacture, use and sale ofLicensed Products, PHS andLicensee wish to adjust the earned royalty rates to reflect these additional intellectual property rights needed to practice the invention.
C.
PHSandLicensee wish to further define the active components of certainCombined Products.
D.
PHS andLicensee wish to expedite the ultimate clinical use ofLicensed Productswhich are at a later stage of development by severing certain legal obligations from otherLicensed Productswhich are at earlier stages of development.
E.
PHS andLicensee have determined the desirability of amending the OriginalAgreementto facilitate the development ofLicensed Productsunder theLicensed Patent Rights.
NOW THEREFORE, in consideration of the mutual covenants set forth herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged,LicenseeandPHS agree to amend theOriginal Agreementas follows:
1.
Section 2.13 (Combined Product).Licensee andPHS hereby agree to amend Section 2.13 (the definition of "Combined Product") of theOriginal Agreement by adding the following at the end of that section:
"For example, [***] and [***] are two-component Combined Products that each contain a Licensed Product and one other active component."
Amendment L-103-9611
PHS and Angiotech Pharmaceuticals, Inc.
March 4, 2002, Page 1 of 5, File: L103961FINAL
2.
Severable Obligations by Licensed Field of Use.
2.1
New Section 13.10.Licensee andPHS hereby agree to add the following as a new Section 13.10 to theOriginal Agreement:
"13.10 As set forth in Section 3.01 and Appendix B, in this Agreement PHS grants Licensee an exclusive license in two different Licensed Fields of Use and a nonexclusive license in a third Licensed Field of Use. All of Licensee's obligations under this Agreement except only those obligations pertaining to royalties and reimbursement under Article 6 (but including, without limitation, obligations pertaining to patent filing, prosecution and maintenance under Article 7, record keeping under Article 8, plans and reports under Article 9, performance under Article 10, infringement and patent enforcement under Article 11 and the obligations listed in Section 13.05) are severable obligations by Licensed Field of Use, not joint obligations of Licensee. Therefore, notwithstanding anything to the contrary set forth in this Agreement, Licensee's unremedied default in the performance of any material obligation under thi s Agreement (except royalty and reimbursement obligations under Article 6) that pertain to only one of the three Licensed Fields of Use shall be a basis for PHS, in accordance with this Article 13, to terminate or modify Licensee's rights under this Agreement as to such Licensed Field of Use, but shall not be a basis for PHS to terminate or modify Licensee's rights in the other Licensed Fields of Use, and all of Licensee's rights and obligations under this Agreement in the other Licensed Fields of Use shall survive, and remain unaffected by, such termination or modification of rights in one Licensed Field of Use."
2.2
Related Amendments to Sections 13.02, 13.04, 13.05 and 13.07.
Licensee and PHS hereby agree to add the phrase ", subject to Section 13.10" (i) in Section 13.02 (after "PHS may" in line 4 of Section 13.02), (ii) in Section 13.05 (both at the beginning of that section and after "PHS may" in the last full line of that section), and (iii) at the beginning of Section 13.07. Licensee and PHS hereby also agree to add the phrase ", on a Licensed Field of Use-by-Licensed Field of Use basis in accordance with Section 13.10," (i) at the end of Section 13.02, after "written notice," (ii) in Section 13.04 after "any licenses", (iii) at the end of Section 13.05, after "terminate this Agreement," and (iv) in Section 13.07 after "modify this Agreement."
3.
Appendix C, Section III (Royalties).Licensee andPBShereby agree to amend Appendix C, Section III, Paragraph A of theOriginal Agreementby adding the following at the end of that Paragraph A, immediately prior to "; and":
";provided that (a), notwithstanding the foregoing, in the case of two-component Combined Products as described in Section 1 of this Amendment that are [***], PHS and Licensee agree that the royalty rates on Net Sales of such Combined Products manufactured and sold in the Licensed Territory shall be (i) [***] percent ([***]%) on Net Sales equal to or less than US$[***] by Licensee or a sublicensee in a given year, and (ii) [***]
Amendment L-103-96/1
Public Health Service and Angiotech Pharmaceuticals, Inc.
March 4, 2002, Page 2 of 5, File: L103961FINAL
[***] percent ([***]%) on Net Sales greater than US$[***] by Licensee or that sublicensee that same year (Licensee shall be entitled to no further reduction of these [***]% and [***]% royalty rates under Paragraph B below, and such royalty rates shall apply to the Net Sales of such Combined Products without further reduction of the Net Sales price under Section 6.12 of thisAgreement);provided further that (b),notwithstanding the foregoing, in the case of two-component Combined Products as described in Section 1 of this Amendment that are [***], PHS and Licensee agree that the royalty rates on Net Sales of such Combined Products manufactured and sold in the Licensed Territory shall be (x) [***] percent ([***]%) on Net Sales equal to or less than US $[***] by Licensee or a sublicensee in a given year, and (y) [***] percent ([***]%) on Net Sales greater than US $[***] by Licensee or that sub licensee that same year, and such [***]% and [***]% royalty rates shall apply to Net Sales of such Combined Products, without further reduction of the Net Sales price under Section 6.12 of this Agreement.
4.
Appendix E — Benchmarks and Performance. Licensee and PHS hereby agree to replace Appendix E of theOriginal Agreementin its entirety with the attachedAmended Appendix E.
5.
This Amendmentshall become effective immediately upon execution by PHS and Licensee.
6.
TheOriginal Agreementshall continue in full force and effect, unchanged except as modified by thisAmendment.
7.
ThisAmendmentmay be executed in multiple counterparts, each of which so executed shall be deemed to be an original, but all such counterparts shall together constitute but one and the sameAmendment.
IN WITNESS WHEREOF, the parties hereto have caused thisAmendmentto beexecuted and delivered by their duly authorized representatives as of the last signature date below.
Amendment L-103-96/1
Public Health Service and Angiotech Pharmaceuticals, Inc.
March 4, 2002, Page 3 of 5, File: L10396IFINAL
FOR PUBLIC HEALTH SERVICE
| | |
/s/Jack Spiegel | | 03/21/2002 |
Jack Spiegel, Ph.D. | | Date |
Direct , Division of Technology Development and Transfer | | |
Office of Technology Transfer | | |
National Institutes of Health | | |
Mailing Address for Notices:
Office of Technology Transfer
National Institutes of Health
6011 Executive Boulevard, Suite 325
Rockville, Maryland 20852-3804 U.S.A.
FOR LICENSEE:
ANGIOTECH PHARMACEUTICALS, 1NC.
/s/William L. Hunter
| | |
| | March 28, 2002 |
Signature | | Date |
William L. Hunter | | |
Printed Name | | |
Chairman & CEO | | |
Title | | |
Mailing Address for Notices:
Angiotech Pharmaceuticals, Inc.
6660 NW Marine Drive
Vancouver, British Columbia
Canada V6T 1Z4
Attention: Vice President and General Counsel
and Vice President, Corporate Development
Any false or misleading statements made, presented, or submitted to theGovernment, including any relevant omissions, under thisAgreement and during the course of negotiation of thisAgreement are subject to all applicable civil and criminal statutes including Federal statutes 31 U.S.C. §§ 3801-3812 (civil liability) and 18 U.S.C. § 1001 (criminal liability including fine(s) and/or imprisonment).
Amendment L-103-96/1
Public Health Service and Angiotech Pharmaceuticals, Inc.
March 4, 2002, Page 4 of 5, File: L103961FINAL
AMENDED APPENDIX E—Benchmarks and Performance
Licenseeagrees to the followingBenchmarksfor its performance underthisAgreementand, within ten (10) days of achieving aBenchmark,shall notifyPHSthat theBenchmarkhas been achieved.
I.
Under the exclusive Licensed Fields of Use for [***]:
1.
[***]
2.
[***]
II.
Under the exclusive Licensed Fields of Use for [***]:
1.
[***]
2.
[***]
3.
[***]
4.
[***]
III. Under thenonexclusive Licensed Fields of Use:
1.
[***]
2.
[***]
Amendment L-103-96/1
Public Health Service and Angiotech Pharmaceuticals, Inc.
March 4, 2002, Page 5 of 5, File: L103961FINAL
